How much does a course of pemigatinib cost?

Pemigatinib is an oral targeted drug mainly used to treat advanced cholangiocarcinoma (CCA) and relapsed or refractory myeloid/lymphoid tumors associated with FGFR1 rearrangements. When many patients and family members first come into contact with pemetinib, one of the questions they are most concerned about is "how much does a course of treatment cost?" This is an important factor in determining the medication plan and financial burden.

Pemetinib is an innovative targeted drug with a relatively high price. For patients with cholangiocarcinoma, the recommended dose is 13.5 mg once daily for 14 days, followed by a 7-day break in a 21-day cycle. This regimen means a fixed dose per cycle. For patients with myeloid or lymphoma tumors associated with FGFR1 rearrangement, pemetinib is administered orally once a day continuously until disease progression or unacceptable toxicity occurs. Therefore, the dosage of the entire course of treatment is relatively large, and the cost also accumulates as the treatment cycle increases.

When patients evaluate the cost of medication, they should make a comprehensive calculation based on the market price of the drug, the length of treatment, and the patient's individualized dose. Clinical practice shows that although pemetinib is more expensive, due to its precise targeting of specific molecular abnormalities, it can improve disease control and quality of life in some advanced patients. Therefore, there is a trade-off between economy and efficacy. For patients whose families are under financial pressure, consider discussing medication assistance programs or clinical trial opportunities with their doctors to reduce the actual burden. It is worth noting that the long-term safety and efficacy of pemetinib depend on regular medication and regular follow-up. Therefore, when evaluating costs, the additional costs of follow-up, laboratory monitoring, and potential side effect management should also be considered.

In short, the cost of each course of pemetinib depends on the indication, dosage regimen and length of treatment. Although the overall price is not low, its precise control effect on patients with specific molecular abnormalities makes it an important treatment option for patients with advanced cholangiocarcinoma andFGFR1 rearranged myeloid/lymphoid tumors.

Reference materials:https://go.drugbank.com/drugs/DB15102